Literature DB >> 9638815

Myxoma virus in rabbits.

P J Kerr1, S M Best.   

Abstract

Myxoma virus in European rabbits (Oryctolagus cuniculus) is one of the best documented examples of host-virus co-evolution. In the natural hosts (Sylvilagus brasiliensis or S. bachmani rabbits in the Americas), myxoma virus causes a benign cutaneous fibroma. In European rabbits, however, myxoma virus causes the fulminant disease, myxomatosis. When introduced into wild European rabbit populations in Australia, Europe and Great Britain, the virus was initially highly lethal, killing in excess of 99% of infected rabbits. Development of resistance was encouraged by the emergence of attenuated virus strains which allowed the survival of moderately resistant rabbits. This may have occurred more rapidly in hot climates, as high ambient temperatures increase the survival rate of infected rabbits. Resistant rabbits are less effective transmitters of the virus and this may encourage the emergence of more virulent virus strains. Little is known of the mechanism of resistance. There have been suggestions of non-genetic resistance. However, these are yet to be confirmed experimentally.

Entities:  

Mesh:

Year:  1998        PMID: 9638815     DOI: 10.20506/rst.17.1.1081

Source DB:  PubMed          Journal:  Rev Sci Tech        ISSN: 0253-1933            Impact factor:   1.181


  12 in total

1.  Horizontal transmissible protection against myxomatosis and rabbit hemorrhagic disease by using a recombinant myxoma virus.

Authors:  J Bárcena; M Morales; B Vázquez; J A Boga; F Parra; J Lucientes; A Pagès-Manté; J M Sánchez-Vizcaíno; R Blasco; J M Torres
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  Molecular characterisation of virulence graded field isolates of myxoma virus.

Authors:  Kevin P Dalton; Ines Nicieza; Aroa Baragaño; Jose Manuel Martín Alonso; Francisco Parra
Journal:  Virol J       Date:  2010-02-26       Impact factor: 4.099

3.  Genome comparison of a nonpathogenic myxoma virus field strain with its ancestor, the virulent Lausanne strain.

Authors:  Mónica Morales; Miguel A Ramírez; María J Cano; Mario Párraga; Joaquín Castilla; Luis I Pérez-Ordoyo; Juan M Torres; Juan Bárcena
Journal:  J Virol       Date:  2008-12-17       Impact factor: 5.103

4.  Molecular species identification, host preference and detection of myxoma virus in the Anopheles maculipennis complex (Diptera: Culicidae) in southern England, UK.

Authors:  Victor A Brugman; Luis M Hernández-Triana; Sean W J Prosser; Chris Weland; David G Westcott; Anthony R Fooks; Nicholas Johnson
Journal:  Parasit Vectors       Date:  2015-08-15       Impact factor: 3.876

5.  Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in mice.

Authors:  Eric Bartee; Mee Y Bartee; Bjarne Bogen; Xue-Zhong Yu
Journal:  Mol Ther Oncolytics       Date:  2016-12-07       Impact factor: 7.200

Review 6.  Potential of oncolytic viruses in the treatment of multiple myeloma.

Authors:  Eric Bartee
Journal:  Oncolytic Virother       Date:  2018-02-23

7.  Safety evaluation of a recombinant myxoma-RHDV virus inducing horizontal transmissible protection against myxomatosis and rabbit haemorrhagic disease.

Authors:  J M Torres; M A Ramírez; M Morales; J Bárcena; B Vázquez; E Espuña; A Pagès-Manté; J M Sánchez-Vizcaíno
Journal:  Vaccine       Date:  2000-09-15       Impact factor: 3.641

8.  Prediction of steps in the evolution of variola virus host range.

Authors:  Chad Smithson; Alex Purdy; Adrian J Verster; Chris Upton
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

9.  Contrasting evolution of virulence and replication rate in an emerging bacterial pathogen.

Authors:  Luc Tardy; Mathieu Giraudeau; Geoffrey E Hill; Kevin J McGraw; Camille Bonneaud
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-01       Impact factor: 11.205

Review 10.  Review of companion animal viral diseases and immunoprophylaxis.

Authors:  J R Patel; J G M Heldens
Journal:  Vaccine       Date:  2008-11-27       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.